Zurück
| Semester | Herbstsemester 2024 |
| Angebotsmuster | Jedes Herbstsemester |
| Dozierende |
Christoph Burkhart (christoph.burkhart@unibas.ch)
Thomas Calzascia (thomas.calzascia@unibas.ch) Tobias Junt (tobias.junt@unibas.ch, BeurteilerIn) Gisbert Weckbecker (gisbert.weckbecker@unibas.ch) |
| Lernziele | The student will understand: - Concepts of basic immunology as a prerequisite for discovery of novel targets and drugs - Medical need in key immunological disorders such as multiple sclerosis, lupus and transplant rejection - Discovery, use and limitations of immunosuppressive drugs - Cell depletion strategies to interfere with autoimmune disorders - Discovery of immunomodulatory drugs, e.g. interference with cell migration, co-stimulation and nucleic acid sensing - Immune activation as a successful treatment option for cancer and infection - PI3 kinase inhibitors as an opportunity to interfere with immune disorders or cancer (e.g. idelalisib and duvelisib) |
| Literatur | Literature List Textbooks (in English): • Kuby Immunology, 8th edition (2018) • Janeway's Immunobiology, 10th edition (2022) • Immunology. A Short Course. 8th Edition (2021), R. Coico G. Sunshine • Cellular and Molecular Immunology, 10th Edition (2021), A. Abbas, A. Lichtman, S. Pillai Check out “Global Immunotalks” on Youtube for related topics Reviews and Papers: Lectures 1 and 2 (Junt) Edner NM, Carlesso G, Rush JS, Walker LSK., Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov. 2020 Dec;19(12):860-883 Junt T, Barchet W (2015), Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 15, 529 Ley K et al (2016), Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 15 (3), 173. Chun J, Brinkmann VA (2011), Mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12(64), 213. Lectures 3 and 5 (Weckbecker) Waring M et al (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat Rev Drug Discov, online, 1. Haijuan Y et al (2013) mTOR kinase structure, mechanism and regulation Nature 497, 217. Gurk-Turner,C et al (2012) A Comprehensive Review of Everolimus Clinical Reports: A New Mammalian Target of Rapamycin Inhibitor Transplantation 94, 659. Amber N. Carrier et al (2022) Xenotransplantation: A New Era (Review) Frontiers in Immunology 13, 1-11 B Sharrack, J Petrie, A Coles, JA Snowden (2022) Is stem cell transplantation safe and effective in multiple sclerosis? BMJ, 377. Willison, A.G., Ruck, T., Lenz, G. et al. (2022) The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. J Neurol 269, 3937–3958. Lecture 4 (Burkhart) Vanhaesebroeck B et al (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5), 329. Lucas C et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 15, 88. Rao VK et al (2017) Effective “activated PI3Kdelta syndrome”-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood 130, 2307 Vanhaesebroeck B et al (2021) PI3K inhibitors are finally coming of age. Nature Rev Drug Discov 20 (10), 471 Lecture 6 (Calzascia) Ribas A and Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade, Science 359(6382), 1350 Chen DS and Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle, Immunity 39(1): 1. Khalil DN et al (2016) The future of cancer treatment: immunomodulation, CARs and combination therapy, Nat Rev Clin Onc 13, 273. Met Ö et al (2019) Principles of adoptive T cell therapy in cancer, Semin Immunopathol 41(1), 49 Fenis, A et al (2024) New immune cell engagers for cancer immunotherapy, Nat Rev Immunol, online AOP |
| Bemerkungen | Researchers in Basel have contributed to the fields of immuno-pharmacology (e.g. cyclosporine, everolimus, ofatumumab, ocrelizumab, fingolimod, PI3 kinase inhibitors, diclofenac) and the lecture will refer to some of these discoveries Film and sound recordings during the course are strictly forbidden (recorders may be confiscated) |
| Weblink | Department of Pharmaceutical Sciences |
| Teilnahmebedingungen | Completed Bachelor degree |
| Unterrichtssprache | Englisch |
| Einsatz digitaler Medien | kein spezifischer Einsatz |
| Intervall | Wochentag | Zeit | Raum |
|---|---|---|---|
| wöchentlich | Mittwoch | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Datum | Zeit | Raum |
|---|---|---|
| Mittwoch 18.09.2024 | 10.15-12.00 Uhr | Biozentrum, Seminarraum U1.191 |
| Mittwoch 25.09.2024 | 10.15-12.00 Uhr | Biozentrum, Seminarraum U1.191 |
| Mittwoch 02.10.2024 | 10.15-12.00 Uhr | Biozentrum, Seminarraum U1.191 |
| Mittwoch 09.10.2024 | 10.15-12.00 Uhr | Biozentrum, Seminarraum U1.191 |
| Mittwoch 16.10.2024 | 10.15-12.00 Uhr | Biozentrum, Seminarraum U1.191 |
| Mittwoch 23.10.2024 | 10.15-12.00 Uhr | Biozentrum, Seminarraum U1.191 |
| Mittwoch 30.10.2024 | 13.45-14.45 Uhr | Biozentrum, Hörsaal U1.141 |
| Module |
Modul: Target Identification/Validation to Discovery of Modulators (Masterstudium: Drug Sciences) Modul: Vertiefung Medizinische Nanowissenschaften (Masterstudium: Nanowissenschaften) Wahlbereich Master Pharmazie: Empfehlungen (Masterstudium: Pharmazie) |
| Leistungsüberprüfung | Lehrveranst.-begleitend |
| Hinweise zur Leistungsüberprüfung | refer to this link: https://pharma.unibas.ch/en/education/assessments-and-credit-points/continuous-assessments/ |
| An-/Abmeldung zur Leistungsüberprüfung | Anm.: Belegen Lehrveranstaltung; Abm.: stornieren |
| Wiederholungsprüfung | keine Wiederholungsprüfung |
| Skala | 1-6 0,5 |
| Wiederholtes Belegen | beliebig wiederholbar |
| Zuständige Fakultät | Philosophisch-Naturwissenschaftliche Fakultät, studiendekanat-philnat@unibas.ch |
| Anbietende Organisationseinheit | Departement Pharmazeutische Wissenschaften |